Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Michael Fluck

Tolerability of BRAF/MEK Inhibitor Combinations: Adverse Event Evaluation and Management

Cancer Research

English

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-Ctla-4 Therapy in Metastatic Melanoma From the Ipilimumab Network

Multidisciplinary

English

Related publications

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancer Research

English

Systems Pharmacology of Adverse Event Mitigation by Drug Combinations

Science Translational Medicine

English

Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?

Oncology in Clinical Practice

English

Trametinib: A MEK Inhibitor for Management of Metastatic Melanoma

OncoTargets and Therapy

English

PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors

Cancer Discovery

English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology

Molecular Biology

English

A Tolerability Burden Index in Schizophrenia: Incorporating Patient Perspective in Clinical Trial Adverse Event Reporting

Journal of Market Access & Health Policy

English

Management of Immune Checkpoint Inhibitor‐related Dermatologic Adverse Events

Thoracic Cancer

Respiratory Medicine

English

BRAF-Inhibitor Auch Langfristig Effektiv

Im Focus Onkologie

English